<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338805</url>
  </required_header>
  <id_info>
    <org_study_id>CBGG492A2212</org_study_id>
    <secondary_id>2010-021448-17</secondary_id>
    <nct_id>NCT01338805</nct_id>
  </id_info>
  <brief_title>Phase II BGG492 Capsule Extension for Partial Epilepsy</brief_title>
  <official_title>A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as
      adjunctive treatment in patients with partial onset seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the long-term safety and tolerability of BGG492 capsules during the maintenance period in patients suffering from partial onset seizures</measure>
    <time_frame>38 weeks</time_frame>
    <description>By measuring the number and percent of patients having any AE (advent event) by primary system organ class and/or preferred term.
By laboratory, vital sign, and ECG data, summary statistics of values and change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy over time by the change in partial seizure frequency original Baseline Period in the double-blind study CBGG492A2207 to the Open-label Extension Maintenance Phase.</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate: To evaluate the maintenance of efficacy by the change in responder rate and numbers of patients becoming seizure free from the original Baseline Period to the Open-label Extension Maintenance Phase.</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure counts: To evaluate the maintenance of efficacy and safety as assessed in percent change of seizure frequency of BGG492 capsules from the original Baseline Period to the Open-label Extension Maintenance Phase.</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate long-term efficacy and safety by summarizing the number and percentage of patients who discontinue due to unsatisfactory therapeutic response effect and for all other reasons.</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Partial Onset Seizures</condition>
  <arm_group>
    <arm_group_label>BGG492</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGG492</intervention_name>
    <arm_group_label>BGG492</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed study CBGG492A2207, cooperated with the study procedures and did not
             experience persistent tolerability issues

          -  Outpatients ≥ 45 kg (99 lb) of weight

          -  Patient would like to continue BGG492 treatment and the investigator believes a
             reasonable benefit from the long-term administration of BGG492 may be expected

          -  Treated with a stable dose of one or a maximum of three licensed Antiepileptic drugs
             (AEDs)and are known to take their medication(s) as directed

          -  Will make themselves available for the study period and are able to record seizures
             and report adverse events themselves or have a caregiver who can record and report the
             events

          -  Provided written informed consent before any extension assessment is performed

        Exclusion Criteria:

          -  Status epilepticus or seizure clusters occurring during study CBGG492A2207 or in the
             period between the end of study the double blind study and the start of study
             CBGG492A2212 for patients experiencing a treatment gap

          -  Have been treated with:

          -  Felbamate, unless treatment has been continuous for ≥ 2 years

          -  Vigabatrin during the 26 weeks prior to the first dose of open-label medication in the
             extension study

          -  Monoamine oxidase (MAO) inhibitors, tricyclic-antidepressants and narcotic analgesics

          -  L-Dopa formulations

          -  Use of concomitant medication that are potential inhibitors of Organic
             anion-transporting polypeptide (OATP) transporters

          -  No physical examination changes suggestive of progressive neurological changes during
             Study CBGG492A2207

          -  Used another investigational drug (other than BGG492) either at the time of enrollment
             in this extension study or within 5 half-lives prior to enrollment in this extension
             study

          -  History of hypersensitivity to the study drug or to drugs of similar chemical classes
             (e.g. sulfonamides) or had multiple drug allergies or one or more severe drug
             reactions to an Antiepileptic drugs (AEDs), including dermatological reactions

          -  Pregnant or nursing (lactating) women

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kehl-Kork</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <disposition_first_submitted>March 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2016</disposition_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Partial onset seizure</keyword>
  <keyword>seizure frequency</keyword>
  <keyword>nervous system diseases</keyword>
  <keyword>central nervous system diseases</keyword>
  <keyword>CNS</keyword>
  <keyword>brain diseases</keyword>
  <keyword>neurologic manifestations</keyword>
  <keyword>adjunctive treatment</keyword>
  <keyword>AEDs</keyword>
  <keyword>antiepileptic drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

